AUPH
Aurinia Pharmaceuticals Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$15.22
-0.13 ▼ -0.85%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$15.26
+0.04 ▲ +0.26%
오리니아 제약(AUPH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$2.0B
스몰캡
P/E
7.0
저평가 구간
배당수익률
없음
52주 위치
61%
저점 +73% · 고점 -21%
애널리스트
매수
C+
Fundamental health
vs. Biotechnology 중형주
수익성 Top 4%
성장 Top 65%
밸류에이션 Top 80%
재무 안정 Top 50%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 2년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 7원. Over the past 2년, it usually traded around 25원. Not because the price dropped, but because earnings grew much faster — this is one of the cheapest stretches of the past 2년.
Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.6 profitable years
| Index | RUT | P/E | 7.03 | EPS (ttm) | 2.16 | Insider Own | 12.11% | Shs Outstand | 130.8M | Perf Week | -0.2% |
| Market Cap | 1.96B | Forward P/E | 12.41 | EPS next Y | 29.05% | Insider Trans | 12.37% | Shs Float | 113.0M | Perf Month | -13.28% |
| Enterprise Value | 1.65B | PEG | - | EPS next Q | 0.24 | Inst Own | 61.83% | Short Float | 8.59% | Perf Quarter | -4.76% |
| Income | 0.30B | P/S | 6.56 | EPS this Y | -54.11% | Inst Trans | 0.88% | Short Ratio | 6.56 | Perf Half Y | 4.75% |
| Sales | 0.30B | P/B | 3.51 | EPS next 5Y | -4.55% | ROA | 48.54% | Short Interest | 9.71M | Perf YTD | -4.58% |
| Book/sh | 4.34 | P/C | 5.17 | EPS past 3/5Y | - | ROE | 64.98% | 52W High | -20.94% ($19.25) | Perf Year | 70.44% |
| Cash/sh | 2.95 | P/FCF | 11.73 | Sales past 3/5Y | 28.3% 41.38% | ROIC | 48.24% | 52W Low | 72.95% ($8.80) | Perf 3Y | 37.49% |
| Dividend Est. | - | EV/EBITDA | 11.03 | EPS Y/Y TTM | 696.05% | Gross Margin | 89.74% | Volatility(W/M) | 3.37% 4.55% | Perf 5Y | 32.35% |
| Dividend TTM | - | EV/Sales | 5.52 | Sales Y/Y TTM | 20.62% | Oper. Margin | 43.58% | ATR (14) | 0.64 | Perf 10Y | 403.97% |
| Dividend Ex-Date | - | Quick Ratio | 5.01 | EPS Q/Q | 53.13% | Profit Margin | 99.97% | RSI (14) | 41.53 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.55 | Sales Q/Q | 24.4% | SMA20 | -4.13% ($15.88) | Beta | 1.43 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/5/7 | SMA50 | -4.73% ($15.98) | Rel Volume | 0.71 | Prev Close | $15.35 |
| Employees | 128 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 28.21% 0.94% | SMA200 | 0.93% ($15.08) | Avg Volume(3M) | 1.48M | Price | $15.22 |
| IPO | 2003/10/20 | Option/Short | Yes/Yes | Trades | 10562 | Volume | 1,056,587 | Change | -0.85% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12
25.3
25.6
25.9
25.12
26.3
Revenue Net income 최근 분기: 매출 $78M (YoY +24%) · 순이익 $34M (YoY +47%)
Aurinia Pharmaceuticals Inc (AUPH) Investment Analysis
What kind of company is Aurinia Pharmaceuticals Inc?
오리니아 제약(AUPH) 초고성장주
Healthcare · Biotechnology
Healthcare Stocks
🧬 This is a biopharmaceutical company that develops and commercializes treatments for autoimmune diseases. It has commercialized an oral therapy targeting kidney disease caused by lupus, and is developing a follow-on pipeline in the autoimmune disease area. As a biopharma company, it combines expanded prescription growth of its commercialized product with pipeline advancement to build its position in the underserved autoimmune disease market.
Learn more about Aurinia Pharmaceuticals Inc →Market Cap
$2.0B
Approx. KRW 2.7 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2123
Employees128people
IPO2003/10/20
Current Price$15.22 ≈ 20,851원
Key Events
⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +28.2% 매출 +0.9%
🔔 Earnings release 2026년 2월 26일 (목) · 장 시작 전 EPS +606.0% 매출 +3.2%
Is it profitable?
Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
43.6%
✓ 우수
Net Margin
Share of revenue left after taxes and interest are paid
100.0%
✓ 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
89.7%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
65.0%
✓ 우수
ROA
Annual earnings relative to total company assets
48.5%
✓ 우수
ROIC
Return generated per dollar invested in the business
48.2%
✓ 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.12
✓ Healthy debt
Current Ratio
Liquid assets available to cover liabilities due within a year
5.55
✓ 평균
Quick Ratio
Liquid assets excluding inventory, available for immediate use
5.01
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$17.00
현재가 대비 +11.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
12.41배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
+29.1%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
-4.5%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+316.4%
평균 서프라이즈
2026.05.07
상회
실적 $0.25 · 예상 $0.20 +26.6%
2026.02.26
상회
실적 $1.53 · 예상 $0.22 +606.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Growth Expected to Slow
Historical growth is expected to lose momentum
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-54.1%
매우 부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+29.1%
평균
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
-4.5%
매우 부진
📊 How much has it grown? (actual results)
Past 5-Year Revenue
How much revenue grew over the past 5 years
+41.4%
양호
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+24.4%
양호
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -36%p below the market
AUPH +32.4% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-36.0%p
Significantly behind the market
vs Health Care (XLV)
+7.9%p
slightly ahead of the sector average
1-year basis
vs S&P 500
+54.4%p
well ahead of the market
vs Health Care (XLV)
+50.7%p
well ahead of the sector average
Rank among peers
5-year return Lower-Mid (lower 44%) Based on 64 peers
1-year return Lower-Mid (lower 40%) Based on 76 peers
Current position within 52-week range
Low (-73.0%p) High (-20.9%p)
Current price is 73.0% above the 52-week low and 20.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-18.3%
Annualized volatility
38.6%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $15.22 below the midline ($15.88). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Bearish momentum holding
MACD -0.254 < Signal -0.149 in negative zone + Hist negative (-0.105). Weakness in progress.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bearish zone
RSI 41.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 12.4.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Assets Cheap
Vs. Sales Cheap
Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
7.03x
✓ Cheap
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
12.41x
✓ Very cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.51x
✓ Very cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
6.56x
✓ Very cheap
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
11.03x
✓ Very cheap
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
11.73x
✓ Very cheap
Analyst target price (reference)
$17.00 vs. current price +11.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology
Who owns it?
Ownership flow is positive
Insider net buying +12.4% · Institutional modest net buying +0.9% · Short interest moderate 8.6%
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
+12.4%
Insiders large net buying
🏦 Institutions (funds & investors)
+0.9%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 61.8%
Adequate institutional weight
🧑💼 Insiders 12.1%
Founder/management large holders (strong skin-in-the-game)
👤 Retail investors (estimated) 26.1%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
8.6%
Moderate
Past 90 days Little change
Short interest days to cover
6.6 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 130.8M주
Float (tradable shares) 113.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding AUPH
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| AUPH This Stock | $2.0B | 7.0 ▲ | 3.5 ▼ | 64.98% ▲ | - | -0.8% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 오리니아 제약(AUPH)?
오리니아 제약(AUPH) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AUPH?
The market cap of AUPH is approximately $2.0B, ranking 2,123 within its sector.
What is the P/E ratio of AUPH?
AUPH has a P/E ratio of approximately 7.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AUPH?
AUPH has recorded a 52-week high of $19.25 and a low of $8.80.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.